Cipla Quarterly Results for Trading Insights
Latest Quarter Net Profit
₹543 Cr
QMar 2026
In Mar 2026, Cipla (CIPLA) reported revenue ₹6,612 Cr and net profit ₹543 Cr — revenue -4.0% YoY. Analyse Cipla shareholding analysis to track promoter, FII and institutional holdings.
CIPLA Quarterly Results — Revenue, Profit & EPS Highlights
Cipla latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. View CIPLA price range for the annual high/low range and current price position.
- Revenue of ₹6,612 Cr in Mar 2026 (-9.3% vs Jun 2026, -4.0% vs Mar 2025)
- Net Profit of ₹543 Cr in Mar 2026 (-30.9% vs Jun 2026, -55.3% vs Mar 2025)
- EBITDA of ₹1,026 Cr in Mar 2026 (-24.6% vs Jun 2026)
- Operating Margin of 14.0% in Mar 2026 (-2.0pp vs Jun 2026)
- Earnings Per Share of ₹6.87 in Mar 2026 (-29.7% vs Jun 2026)
Cipla Quarterly Results — Revenue, EBITDA, Net Profit & EPS
CIPLA quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 6,612 | 7,288 | 7,716 | 6,887 | 7,096 | -9.3% | -4.0% |
| Net Profit (₹ Cr) | 543 | 786 | 1,353 | 1,214 | 1,292 | - | - |
| EBITDA (₹ Cr) | 1,026 | 1,361 | 2,022 | 1,695 | 1,916 | - | - |
| EPS (₹) | 6.87 | 9.77 | 16.73 | 15.13 | 16.07 | - | - |
| Operating Margin (%) | 14.0% | 16.0% | 24.0% | 21.0% | 24.0% | - | - |
CIPLA Share Price Trend — 1-Year Movement Across Quarterly Results
Cipla 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit CIPLA share price screener.
Revenue Trend (₹ Cr)
Mar 2025
6,887
Sept 2025
7,716
Jun 2026
7,288
Mar 2026
6,612
Net Profit Trend (₹ Cr)
Mar 2025
1,214
Sept 2025
1,353
Jun 2026
786
Mar 2026
543
Operating Margin Trend (%)
Mar 2025
21.0%
Sept 2025
24.0%
Jun 2026
16.0%
Mar 2026
14.0%
CIPLA vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Cipla latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹441,477.63 Cr | 1837.3 | 15,018 | 2,710 | -5.6% | - | 18.0% | 162.6 |
|
Divis Laboratories
Mar 2026 |
₹247,469.81 Cr | 9375.0 | 2,986 | 751 | -5.0% | - | 25.2% | 331.2 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4840.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 420.5 |
|
Zydus Life Science
Mar 2026 |
₹112,607.65 Cr | 1160.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 91.7 |
|
Laurus Labs
Mar 2026 |
₹103,852.21 Cr | 1954.0 | 1,823 | 282 | -10.5% | - | 15.5% | 377.9 |
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores
All amounts in ₹ Crores